1. The 5-year overall survival had a hazard ratio of 0.49, and this benefit was generally consistent across subgroups (stage, EGFR mutation, race) as well as adjuvant chemotherapy status 2. Safety was consistent with prior analysis and no new adverse events were reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Resectable non-small cell lung cancer